Health Condition 1: E785- Hyperlipidemia, unspecified
Conditions
Interventions
Intervention1: AYRL Capsule: AYRL Capsule contains Commiphora mukul, Terminalia arjuna, Andrographis paniculata Bergenia ligulata, Zingiber officinale, Crataeva nurvala, Piper longum
Dosage and Trea
Sponsors
Welex Laboratories Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects diagnosed of Dyslipidemia (LDL-C between 130 and 190 mg/dl or Triglycerides between 150 and 500 mg/dL or TC >= 240 mg/dl but not more than 400 mg/dl) who are not taking any Hypo-lipidemic agents including Statins 2.Subjectâ??s ECG not demonstrating any signs of uncontrolled arrhythmia / acute ischemia. 3.A urine pregnancy test will be required for all female subjects unless subject has had a hysterectomy, tubal ligation, or is > 2 years post menopause. 4.Female subjects who agree to avoid pregnancy during the study and one month after the end of the study by using reliable method of contraception. 5.Subjects willing to follow the procedures as per the study protocol and voluntarily signing informed consent form.
Exclusion criteria
Exclusion criteria: 1.Subjects with myocardial infarction, stroke, transient ischemic attack, cardiovascular surgery or major operations or any significant cardiovascular event within 6 months prior to screening visit. 2.Subjects with history of gastric or peptic ulcer within 3 months prior to screening visit. 3.Subjects with uncontrolled diabetes mellitus and uncontrolled hypertension 4.Subjects with medical history of pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, or primary biliary cirrhosis within last six months. 5.Subjects of Hypothyrodism with TSH levels of >10mg% will be excluded 6.Subjects with liver dysfunction as indicated by a serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) level of > 1.5-times of upper limit of normal range, or clinical symptoms. 7.Subjects with clinical significant renal dysfunction as per investigatorâ??s opinion 8.Subjects having an active malignancy and tuberculosis. 9.Subjects with history of chronic, contagious infectious disease, such as active tuberculosis or Hepatitis B or C or HIV. 10.Use of any other investigational drug within 1 month prior to randomization 11.Known hypersensitivity to ingredients used in study drugs 12.Pregnant and Lactating females. 13.Any other condition, which in the opinion of investigator will place the subject at risk or will influence the conduct of study or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Comparative change in Low density Lipoprotein (LDL) levels after three months of treatment between the groups 2.Comparative change in Serum Triglycerides and Total Cholesterol levels after 90 days of treatment between the groups Timepoint: Day -7, Day 45, Day 90 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Comparative changes in HDL, VLDL, TC/ HDL ratio, LDL/HDL ratio between the groups 2.Changes in Cardiac biomarkers between the groups 3.Monthly changes in weight, BMI, waist circumference, Hip Circumference, waist: Hip ratio in the two groups. 4.Monthly changes in BMR, Body fat percentage, total body water, LBM between the groups 5.Global assessment for overall change by the investigator and subject 6.Change in Laboratory parameters, vitals and ADRs and ECGTimepoint: Day -7, Day 45, Day 90 | — |
Countries
India
Contacts
Public ContactDr Sanjay Tamoli
Target Institute of Medical Education and Research
Outcome results
None listed